C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients

British Journal of Cancer

Volumn 111, Issue 1, 2014, Pages 55-60

  Troppan, K T ^a   Schlick, K ^b   Deutsch, A ^a   Melchardt, T ^b   Egle, A ^b   Stojakovic, T ^a   Beham Schmid, C ^a   Weiss, L ^b   Neureiter, D ^b   Wenzl, K ^a   Greil, R ^b   Neumeister, P ^a   Pichler, M ^a,c  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

DLBCL; inflammatory parameter; prognosis

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVISED INTERNATIONAL PROGNOSTIC INDEX;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; C-REACTIVE PROTEIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84904133251     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.277     Document Type: Article

References (34)

1. Absenger G, Szkandera J, Pichler M, Stotz M, Arminger F, Weissmueller M, Schaberl-Moser R, Samonigg H, Stojakovic T, Gerger A (2013) A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer 109(2): 395-400.
2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson Jr J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO,Warnke R, Levy R,WilsonW, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769): 503-511.
3. Allin KH, Nordestgaard BG (2011) Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 48(4): 155-170.
4. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES (2011) WHO classification of tumours of hematopoietic and lymphoid tissues. Blood 117(19): 5019-5032.
5. Cao Y, Shi YX, Chen JO, Tan YT, Cai YC, Luo HY, Qiu MZ, Cai XY, Jin Y, Sun YL, Jiang WQ (2012) Serum C-reactive protein as an important prognostic variable in patients with diffuse large B cell lymphoma. Tumour Biol 33(4): 1039-1044.
6. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917): 860-867.
7. Elahi MM, McMillan DC, McArdle CS, Angerson WJ, Soukop M, Johnstone J, Sattar N (1998) The systemic inflammatory response predicts overall and cancer specific survival in patients with malignant lymphoma. Leuk Lymphoma 31(3-4): 351-357.
8. Flowers CR, Sinha R, Vose JM (2010) Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin 60(6): 393-408.
9. Groblewska M, Mroczko B, Sosnowska D, Szmitkowski M (2012) Interleukin 6 and C-reactive protein in esophageal cancer. Clin Chim Acta 413(19-20): 1583-1590.
10. Hall WA, Nickleach DC, Master VA, Prabhu RS, Rossi PJ, Godette K, Cooper S, Jani AB (2013) The association between C-reactive protein (CRP) level and biochemical failure-free survival in patients after radiation therapy for nonmetastatic adenocarcinoma of the prostate. Cancer 119(18): 3272-3279.
11. Harrell Jr FE, Califf RM, Pryor DB, Lee KL, Rosati RA (1982) Evaluating the yield of medical tests. JAMA 247(18): 2543-2546.
12. Herishanu Y, Perry C, Braunstein R, Metser U, Goor O, Rogowski O, Berliner S, Polliack A, Naparstek E (2007) Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin's lymphoma. Eur J Haematol 79(2): 150-154.
13. Hong S, Kang YA, Cho BC, Kim DJ (2012) Elevated serum C-reactive protein as a prognostic marker in small cell lung cancer. Yonsei Med J 53: 111-117.
14. Legouffe E, Rodriguez C, Picot MC, Richard B, Klein B, Rossi JF, Commes T (1998) C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leuk Lymphoma 31(3-4): 351-357.
15. Lenz G, Staudt LM (2010) Aggressive lymphomas. N Engl J Med 362: 1417-1429.
16. Li YJ, Jiang WQ, Huang JJ, Xia ZJ, Huang HQ, Li ZM (2013b) The Glasgow Prognostic Score (GPS) as a novel and significant predictor of extranodal natural killer/T-cell lymphoma, nasal type. Am J Hematol 88(5): 394-399.
17. Li YJ, Li ZM, Xia Y, Huang JJ, Huang HQ, Xia ZJ, Lin TY, Li S, Cai XY, Wu-Xiao ZJ, Jiang WQ (2013a) Serum C-reactive protein (CRP) as a simple and independent prognostic factor in extranodal natural killer/T-cell lymphoma, nasal type. PLoS One 8(5): E64158.
18. Pavlidis AN, Kalef-Ezra J, Bourantas LC, Lambrou A, Mavridis A (1993) Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia. Int J Biol Markers 8(1): 14-20.
19. Pichler M, Hutterer GC, Stoeckigt C, Chromecki TF, Stojakovic T, Golbeck S, Eberhard K, Gerger A, Mannweiler S, Pummer K, Zigeuner R (2013b) Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer 108(4): 901-907.
20. Pichler M, Hutterer GC, Stojakovic T, Mannweiler S, Pummer K, Zigeuner R (2013a) High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients. Br J Cancer 109(5): 1123-1129.
21. Poole EM, Lee IM, Ridker PM, Buring JE, Hankinson SE, Tworoger SS (2013) A prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor a receptor 2 levels and risk of ovarian cancer. Am J Epidemiol 178(8): 1256-1264.
22. Porrata LF, Ristow K, Habermann T, Inwards DJ, Micallef IN, Markovic SN (2010) Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. Am J Hematol 85(11): 896-899.
23. Porrata LF, Ristow KM, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski G, Thompson CA, Markovic SN (2014) Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma; e-pub ahead of print 19 March 2014.
24. PurdueMP, Hofmann JN, Kemp TJ,ChaturvediAK, LanQ, Park JH, Pfeiffer RM, Hildesheim A, Pinto LA, Rothman N (2013) A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma. Blood 122(6): 951-957.
25. Ramsey S, Lamb GW, Aitchison M, McMillan DC (2006) The longitudinal relationship between circulating concentrations of C-reactive protein, interleukin-6 and interleukin-10 in patients undergoing resection for renal cancer. Br J Cancer 95(8): 1076-1080.
26. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 346(25): 1937-1947.
27. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5): 1857-1861.
28. Shipp MA on behalf of The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329(14): 987-994.
29. Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Samonigg H, Maurer-Ertl W, Stojakovic T, Ploner F, Leithner A, Pichler M (2013b) Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients. Br J Cancer 109(9): 2316-2322.
30. Szkandera J, Stotz M, Absenger G, Stojakovic T, Samonigg H, Kornprat P, Schaberl-Moser R, Alzoughbi W, Lackner C, Ress AL, Seggewies FS, Gerger A, Hoefler G, Pichler M (2013a) Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br J Cancer 110(1): 183-188.
31. Toiyama Y, Fujikawa H, Koike Y, Saigusa S, Inoue Y, Tanaka K, Mohri Y, Miki C, Kusunoki M (2013) Evaluation of preoperative C-reactive protein aids in predicting poor survival in patients with curative colorectal cancer with poor lymph node assessment. Oncol Lett 5(6): 1881-1888.
32. Troppan K, Deutsch A, Gerger A, Stojakovic T, Beham-Schmid C, Wenzl K, Neumeister P, Pichler M (2014) The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Br J Cancer 110(2): 369-374.
33. Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J, Wan B, Kwak LW, Yu L, Yi Q (2007) Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 12(3): 252-265.
34. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN (2014) An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123(6): 837-842.